Guangping Gao

Guangping Gao is a world-leading expert in adeno-associated virus (AAV) biology and gene therapy vector development. His laboratory has discovered hundreds of novel AAV variants from human and non-human primate tissues, significantly expanding the AAV vector toolkit. Gao's work on AAV9 has been particularly transformative, enabling systemic delivery to the central nervous system and leading to the first FDA-approved gene therapy for spinal muscular atrophy (Zolgensma).

高光平是AAV生物学和基因治疗载体开发领域的世界顶级专家。他的实验室从人类和非人灵长类动物组织中发现了数百种新型AAV变体，显著扩展了AAV载体工具包。高光平在AAV9方面的工作尤为具有变革性，使系统性递送到中枢神经系统成为可能，并促成了首个FDA批准的脊髓性肌萎缩症基因治疗药物（Zolgensma）。